The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. - Wikidata - wikimedia - TriplyDB

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

http://www.wikidata.org/entity/Q30494514

about

Targeting the hepatocyte growth factor-cMET axis in cancer therapy Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?c-Met as a Target for Personalized Therapy Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma Biology of MET: a double life between normal tissue repair and tumor progression Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma Detection of hepatocyte growth factor (HGF) ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assay Novel insight into mutational landscape of head and neck squamous cell carcinoma The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma.A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment Clinical update on cancer: molecular oncology of head and neck cancer PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.MET receptor tyrosine kinase Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274 Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma Small molecule c-Met kinase inhibitors: a review of recent patents.Comparative analysis of algorithms for integration of copy number and expression data.Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee Tongue carcinoma infrequently harbor common actionable genetic alterations Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7 Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis.Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase Bitter melon reduces head and neck squamous cell carcinoma growth by targeting c-Met signaling.Receptor-tyrosine-kinase-targeted therapies for head and neck cancer.Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.The role of the c-Met pathway in lung cancer and the potential for targeted therapy.DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer Determination of a novel anticancer c-Met inhibitor LS-177 in rat plasma and tissues with a validated UPLC-MS/MS method: application to pharmacokinetics and tissue distribution study.Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle.c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer.Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR

P2860

Q24606259-AF6C8673-1735-40D0-A2DB-45F9CD06E04C Q26748581-0698DF21-404B-4D77-A564-7B2EB9AC0F7D Q26775483-A1C74484-F383-45AB-BDE7-016F36920EB8 Q26852215-5E164A75-AA52-4C06-929F-484309C7EB44 Q28074691-0C9626B0-E6CD-48D3-BEC4-3B024EF78E04 Q28085247-0EC4BCB8-939B-4B23-BB5F-B6A1D6052C04 Q28540413-40477DCD-0199-43F6-9D42-F9D37F3A1A60 Q28743359-0EDAD38D-B34C-4963-A23E-173B1FE81AF3 Q30441193-3D8336E8-E30A-4157-B2BE-6D83B34BE17B Q30534479-8F450DA6-754C-4B87-8F11-69B4E5FA4600 Q33365218-12EFD99A-8D66-4DAB-B471-3B6D07B9A603 Q33541323-898A1F5F-D6B4-4A26-980E-39C14152AED8 Q33607965-41A2AFFC-BB7B-4A61-AB7A-CD95CD80A8B4 Q33695197-F96925E7-384B-4500-8878-5EC74EF5E159 Q33717395-3DC56724-8229-4DDB-8DB5-AA56AABE3776 Q33725229-0C21057D-8A6F-4890-9CB6-0E28566C2CEA Q33756836-95435C4F-ACC9-4FFC-950B-3B52B4B14B98 Q33823715-8C1A3537-4C92-49CD-AB69-8D4199972BD4 Q33901521-ED979384-297A-4B0B-90E5-B52E5AB50F70 Q33918113-915DAB91-F9EB-4376-B53E-32677CBF08EF Q34094632-F5618226-DCB1-446C-826B-68329D3BB0F4 Q34156955-84722398-782C-4926-9F36-59F2E6394A0B Q34160540-7A2E482D-CB09-4A7C-9AFC-40E844697726 Q34256064-E9ED1B95-215B-4D6E-AA85-EBDB793A0AB8 Q34273411-29FA7B6C-3CBA-4CB0-BBEB-824E7C03F171 Q34463471-59B12A3A-5EC8-4BBE-9FCD-CF1B6D3907C2 Q34613189-016EA6F8-08B4-4775-AEB2-87F5196FC1C8 Q34627751-2E3D9502-90B0-4750-8BCC-3F9744621F70 Q34883707-88205247-2116-47CF-87D6-B4D24396128D Q35023515-E42AF945-897D-499B-8C35-4502FB781C43 Q35102025-6F0073A8-E45F-4045-A29C-0DEEC88FD8EB Q35110418-2E5F1241-8722-4031-97D8-10D43C803AD2 Q35146937-D2CF57FC-7DBE-4C70-B4C9-8674AAC03B0D Q35206363-35F77683-F10A-4B55-97EA-7B626AF4108C Q35487148-2C3DCA96-278B-40DA-B62B-0D3AAEF8CE76 Q35582737-7282E01D-AB90-4817-8108-19702EE433CA Q35650167-528C784C-3181-4D73-99FD-200B497CAA23 Q35836427-0CEFD0C2-0788-4650-85C3-4EA59366A418 Q36005545-0F6CE1FC-3F2F-46B2-B573-DD39017466FE Q36090422-07AAC0EA-4708-4003-8D48-4832B3AB6EDF

P2860

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

http://www.wikidata.org/entity/Q30494514

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

The MET receptor tyrosine kina ...... neck squamous cell carcinoma.

@ast

The MET receptor tyrosine kina ...... neck squamous cell carcinoma.

@en

type

label

The MET receptor tyrosine kina ...... neck squamous cell carcinoma.

@ast

The MET receptor tyrosine kina ...... neck squamous cell carcinoma.

@en

prefLabel

The MET receptor tyrosine kina ...... neck squamous cell carcinoma.

@ast

The MET receptor tyrosine kina ...... neck squamous cell carcinoma.

@en

P1433

Q30494514-4EB45C30-F437-4CBB-BC69-A0166C7868EC

P1476

Q30494514-56ED38F3-0476-4DE3-BDF5-5ECBF98004F2

P2093

Q30494514-004B8FEF-89C8-4417-9B0C-A3FEC296E4E4

Q30494514-04340910-DB72-48CE-ACF0-F234D26CFCA8

Q30494514-1A88A83F-1B3F-40D5-8559-D77C376503AF

Q30494514-2582BD86-56D6-43A4-80FF-C463C11E33B4

Q30494514-25F7CB50-0B18-48E5-9120-06C9CA19D501

Q30494514-760EA899-9E23-4FFC-BD0A-AF9E7F910721

Q30494514-7A59DF10-9DE5-4CA6-9B49-099E2FCA3031

Q30494514-7EC35550-2466-4612-B036-3039C404F8C2

Q30494514-82764E12-D9EA-490A-BEC8-3DF1A6ABC2F4

Q30494514-9500C02F-AE2C-44C8-B002-F84C113B59CC

P2860

Q30494514-066FED35-1D88-4351-A1B6-7BB1F51EABB3

Q30494514-0E94D71C-4F7B-4DD9-8788-A61992D72025

Q30494514-10AB3A6A-32CE-41DE-981C-D82F0B6AED53

Q30494514-1136817A-AA14-416C-9310-9BF6D5B3E179

Q30494514-13B9C6B2-3427-459D-A147-A6E6CC5C75F8

Q30494514-2437FC8E-9602-426A-8147-2F8AE3D083F9

Q30494514-2667F027-17F2-43FC-88E4-EDF292A6F21B

Q30494514-277D4CE4-7A68-4BE5-B7AE-7403DB9850D2

Q30494514-2C98E537-795F-4AAD-A0D6-DB3ACBD1C378

Q30494514-30EDF316-70F1-4CA8-A65C-D52F6962026A

P304

Q30494514-1BE4B5EF-BD2C-4913-8BB0-DA3123D92303

P31

Q30494514-9DC0D630-8A84-4733-994A-0F3442EA6D22

P356

Q30494514-4A337A33-EB02-4ABB-B56F-76EBEB9B5157

P407

Q30494514-53D18D94-C897-4893-AA65-1A7ED6D59A90

P433

Q30494514-3EDCBA1C-8E63-42D3-8E9C-46AEE9C6028F

P478

Q30494514-6EAC087B-A9EE-4E16-A648-74006BACC985

P50

Q30494514-805FC0DA-E670-4B8E-9BBA-A9172FCE60D7

Q30494514-F8BFF42E-E171-4BEF-85F9-AB9756879522

P577

Q30494514-387D2D20-A0E2-40F9-8E49-A7C4CE527FB2

P698

Q30494514-E879A7C0-EFA7-456B-9D01-F8D1071400A2

P932

Q30494514-5716BAB0-C649-47AB-A2C9-3A6220CFF583

P356

0008-5472.CAN-08-2881

P1433

Cancer Research

P1476

The MET receptor tyrosine kina ...... neck squamous cell carcinoma.

@en

P2093

Andres Klein-Szanto

http://www.w3.org/2001/XMLSchema#string

Ezra E W Cohen

http://www.w3.org/2001/XMLSchema#string

James G Christensen

http://www.w3.org/2001/XMLSchema#string

Leonardo Faoro

http://www.w3.org/2001/XMLSchema#string

Leslie Martin

http://www.w3.org/2001/XMLSchema#string

Mark W Lingen

http://www.w3.org/2001/XMLSchema#string

Mohamed El Dinali

http://www.w3.org/2001/XMLSchema#string

Rajani Kanteti

http://www.w3.org/2001/XMLSchema#string

Ramasamy Jagadeeswaran

http://www.w3.org/2001/XMLSchema#string

Soheil Yala

http://www.w3.org/2001/XMLSchema#string

P2860

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Cancer statistics, 2008

c-Met: structure, functions and potential for therapeutic inhibition

Targeting the c-Met signaling pathway in cancer

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

P304

3021-3031

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-08-2881

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Everett E Vokes

P577

2009-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19318576

http://www.w3.org/2001/XMLSchema#string

P932

2871252

http://www.w3.org/2001/XMLSchema#string